Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors
about
Current clinical immunotherapeutic approaches for head and neck cancerNew Strategies for the Treatment of Solid Tumors with CAR-T CellsChimeric antigen receptor T-cell therapy for solid tumorsMesothelin-Targeted CARs: Driving T Cells to Solid TumorsHigh-content molecular profiling of T-cell therapy in oncologyDiacylglycerol Kinases in T Cell Tolerance and Effector FunctionDesigning chimeric antigen receptors to effectively and safely target tumorsLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesTIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis.Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsIdentification and selective expansion of functionally superior T cells expressing chimeric antigen receptorsSeatbelts in CAR therapy: How Safe Are CARS?Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in MiceCellular and molecular immunology of lung cancer: therapeutic implications.Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade.Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulationChimeric antigen receptor T cells: a novel therapy for solid tumors.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptorsGeneration of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric ImmunoreceptorsRedundant and specialized roles for diacylglycerol kinases α and ζ in the control of T cell functions.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Immunotherapy for advanced melanoma: future directions.Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
P2860
Q26745411-60387D64-F4F2-49B2-9682-2F708E7409ACQ26748500-9FB58102-0E6A-4020-A471-CF7B844FB7CFQ26750908-92A4F144-1E58-4CF9-93B7-E535E4501A17Q26778759-D1DE4782-F647-43CC-8ABE-304F07432E03Q28066792-3A84391C-B3F7-4F16-B584-120366227F6FQ28079616-BA75CE06-5A06-4BA4-A1CC-F506988F7AF1Q28088526-1970969B-7F65-408B-9285-0C471D878087Q28395597-41F7CFBC-C036-40F4-9994-BBCC74FC2812Q33761878-A6C2F298-E860-4ACF-ABFA-322C9FBC9B6DQ34047618-A2AE4668-E048-48C8-99B8-7C07BA10F89CQ34487189-1A436417-AE2F-4E0B-987F-7654AFE14593Q34517676-DF39D258-CF91-417E-986F-177AF3760B2FQ34934191-2586EA10-3057-4D19-ACEC-6F9D05BCBF11Q35506724-603D6EE7-98A4-41EC-8C69-7A51D9317532Q35627284-E3BB8B17-7993-4404-A29E-5693F7DEF02BQ35673240-AF98A988-4D3E-4C57-A392-226EFE70BBE9Q35689938-07F59262-5659-4154-9D62-DCD6C43BB7ABQ35818365-6CD9CBBD-3327-4A96-9EDD-CEC7200A7494Q36028047-5D3B72D0-7270-498C-A4A8-BAF2FF3DFBD6Q36130505-6C7A2EC6-EB9C-4BA4-8750-F35E9A4DDA9FQ36259431-2014BB7B-7EEE-4A6E-B85E-C296C050D2FCQ36299762-36931B6A-E8E8-4E0C-A03E-A0081A884E87Q36471557-B90C55C7-EC15-48A1-A955-D887F6385F6DQ36709308-84FFF7D4-876D-4BB9-8108-B10D6A593089Q36963494-FB9A645A-9176-4085-AE8D-3E6DABB7E677Q37137924-7F0D5C6C-9316-48F5-9E4B-CF1DB8B2E84FQ37559401-941D0C77-8843-458E-BD24-D495E1D8A61CQ37566921-61E8698D-FEAF-4DCE-9585-D5A8D9FBCCD3Q37578210-31DE171F-C728-4422-8243-7999E0535378Q37655345-60B7393A-1AE3-4652-A78A-0B585A3CFE59Q37728639-430DA60A-16BF-4592-BCBA-A7979660C614Q38289029-6D118032-29EF-43C9-A736-3CCDDB18C668Q38291751-4F7F7F82-5241-4529-88E8-2E839A5281E7Q38426341-94ABE7B8-55FD-484A-9140-02ED45356727Q38447171-CE241693-76CA-4645-9ED1-2CB811B6AE0EQ38525024-6EFF7955-A472-49CD-A796-F87049B1A31DQ38711163-A58D3491-A700-46CF-8A54-B6C78B47B273Q38758789-1A573670-EEFB-41F8-AC42-2A7333F1BB68Q38769271-2BECECD1-8B5B-4AB9-A68A-F0C7EDD35E90Q38770555-09CE06CA-A918-4B40-A9DD-8765647BA95B
P2860
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@ast
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@en
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@nl
type
label
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@ast
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@en
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@nl
prefLabel
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@ast
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@en
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@nl
P2093
P2860
P1476
Multifactorial T-cell hypofunc ...... human T cells in solid tumors
@en
P2093
Caleph B Wilson
Carl H June
Douglas V Dolfi
E John Wherry
Edmund K Moon
Ellen Puré
John Scholler
Liang-Chuan Wang
Michael C Milone
P2860
P304
P356
10.1158/1078-0432.CCR-13-2627
P407
P577
2014-06-11T00:00:00Z